
Gilead's twice-yearly HIV PrEP set for wider rollout
The WHO has recommended Gilead's twice-yearly HIV PrEP drug lenacapavir, calling it 'transformational', but there are concerns about patient access.

UK Biobank charts success of NHS imaging project
The UK Biobank has completed the world's largest whole body imaging project, compiling more than a billion scans from 100,000 volunteers.


New cystic fibrosis triple from Vertex backed for NHS use
Vertex has won NICE's backing for a new cystic fibrosis therapy, Alyftrek, that could be an option for 89% of NHS patients with the genetic disorder.

What to do when your grant application fails
All hope should not be lost and an unsuccessful application doesn’t always mark the end of the road.
Featured Content
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content

The Inaugural Market Access for CNS Therapeutics Summit Has ...
The only dedicated forum focused on tackling the unique commercial and reimbursement challenges facing treatments for neurodegeneration...

5th Oligonucleotides for CNS Summit
The Oligonucleotides for CNS Summit returns for its 5th year to address key challenges in durability, scalability, potency and CNS tropism

Immune Cell Engager Partnering & Investment Summit
Driving high ROI across immune cell engagers through strategic partnerships & investments, capitalizing on novel targets & asset tunability...

2nd ADC & Novel Conjugates Partnering & Investment Summit
Refine your strategy, sharpen your positioning, and meet the right partners - all at the most efficient networking event of the ADCconference calendar

2nd Autoimmunity & Inflammation Partnering & Investment Summ...
Driving deal-making across targeted cell depletion, checkpoint agonism, tolerance, and oral anti-inflammatory biologics...